The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.
The FDA has granted expanded access to Revolution Medicines’ targeted pancreatic cancer drug daraxonrasib, opening a pathway for more patients to receive a therapy that has shown promising results in clinical trials.
The U.S. FDA approves expanded access to daraxonrasib, a breakthrough targeted therapy for previously treated metastatic pancreatic ductal adenocarcinoma, offering new hope for patients with one of the deadliest cancers.
The US FDA approves expanded access to daraxonrasib, an innovative pancreatic cancer drug, offering new hope for patients facing one of the deadliest forms of cancer.
The FDA approves an expanded access program for daraxonrasib, an innovative pancreatic cancer drug that showed promising results in clinical trials, offering new hope for patients with one of the most challenging cancers.
The U.S. FDA approves expanded early access for the experimental pancreatic cancer drug daraxonrasib, offering new hope for late-stage patients.
A Mayo Clinic-developed AI system called REDMOD can identify pancreatic cancer signatures from CT scans an average of 16 months before clinical diagnosis, with a detection rate nearly double that of human specialists.
Mayo Clinic announced a breakthrough research finding: its AI model can detect invisible tissue changes of pancreatic cancer up to 3 years before diagnosis, demonstrating unprecedented early detection capabilities in a landmark validation study.
Mayo Clinic publishes a landmark validation study showing its AI model can detect early tissue changes of pancreatic cancer in routine CT scans, identifying the disease years before traditional diagnosis.
Researchers at Mayo Clinic have developed an AI model that can detect ‘invisible’ tissue changes of pancreatic cancer years before symptoms appear, marking a major breakthrough in early cancer screening.